|
||


* Department of Molecular Biology and Pharmacology, Studies in cell culture systems have indicated
that oncogenic forms of Ras can affect apoptosis. Activating mutations of Ras occur in ~30% of all human
tumors and 50% of colorectal carcinomas. Since these
mutations appear at early or intermediate stages in multistep journeys to neoplasia, an effect on apoptosis
may help determine whether initiated cells progress towards a more neoplastic state. We have tested the effects of K-rasVal12 on apoptosis in transgenic mice. A
lineage-specific promoter was used to direct expression
of human K-rasVal12, with or without wild-type (wt) or
mutant SV-40 T antigens (TAg), in postmitotic villus
enterocytes, the principal cell type of the small intestinal epithelium. Enterocytes can be induced to reenter
the cell cycle by TAgWt. Reentry is dependent upon the
ability of TAg to bind pRB and is associated with a p53-independent apoptosis. Analyses of K-rasVal12 × TAgWt
bi-transgenic animals indicated that K-rasVal12 can enhance this apoptosis threefold but only in cycling cells; increased apoptosis does not occur when K-rasVal12 is
expressed alone or with a TAg containing
Glu107,108
Department of Surgery, Washington University School of Medicine, St.
Louis, Missouri 63110
Lys107,108 substitutions that block its ability
to bind pRB. Analysis of bi-transgenic K-rasVal12 × TAgWt mice homozygous for wild-type or null p53 alleles established that the enhancement of apoptosis occurs through a p53-independent mechanism, is not attributable to augmented proliferation or to an increase
in abortive cell cycle reentry (compared to TAgWt
mice), and is not associated with detectable changes in
the crypt-villus patterns of expression of apoptotic regulators (Bcl-2, Bcl-xL, Bak, and Bax) or mediators of
epithelial cell-matrix interactions and survival (e.g.,
5
1 integrin and its ligand, fibronectin). Coexpression
of K-rasVal12 and TAgWt produces dysplasia. The
K-rasVal12-augmented apoptosis is unrelated to this dysplasia; enhanced apoptosis is also observed in cycling
nondysplastic enterocytes that produce K-rasVal12 and a
TAg with a COOH-terminal truncation. The dysplastic
epithelium of K-rasVal12 × TAgWt mice does not develop neoplasms. Our results are consistent with this
finding: (a) When expressed in initiated enterocytes
with a proliferative abnormality, K-rasVal12 facilitates
progression to a dysplastic phenotype; (b) by diminishing cell survival on the villus, the oncoprotein may impede further progression; and (c) additional mutations
may be needed to suppress this proapoptotic response
to K-rasVal12.
This article has been cited by other articles:
|
|